<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95769">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905956</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/010013</org_study_id>
    <nct_id>NCT01905956</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IQP- AK-102 in Reducing Body Weight</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of IQP- AK-102 in Reducing Body Weight in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several
      studies demonstrating their efficacy, we are conducting this study to look into the efficacy
      and safety of this novel combination of glucomannan, kappa-carrageenan and xanthan gum, in
      appetite regulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Difference in the mean change in body weight between the two arms</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured in kg using calibrated weighing scales</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist and hip circumference (cm)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat content and fat free mass</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food craving questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of efficacy by the subjects and investigators</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of safety by the subjects and investigators</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Weight Loss</condition>
  <condition>Appetite Management</condition>
  <arm_group>
    <arm_group_label>IQP-AK-102</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsules per dose, three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules per dose, 3 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQP-AK-102</intervention_name>
    <arm_group_label>IQP-AK-102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  25≤BMI≤35

          -  Expressed desire for weight loss

          -  Accustomed to 3 main meals/day

          -  Generally in good health

          -  Consistent and stable body weight 3 months prior to study enrolment

          -  Consistent regular physical activity

          -  Commitment to avoid the use of other weight loss products during study

          -  Commitment to adhere to diet and lifestyle recommended for the study

        Exclusion Criteria:

          -  Known sensitivity to the ingredients of the device (glucomannan, kappa- carrageenan
             and xanthan gum)

          -  Presence of any active gastrointestinal disease

          -  Malabsorption disorders

          -  Pancreatitis

          -  Stenosis in the GI tract

          -  Bariatric surgery

          -  Any other reason deemed suitable for exclusion, per investigator's judgement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Grube, MD</last_name>
      <phone>+49 30/892 1030</phone>
      <email>bgrube@web.de</email>
    </contact>
    <investigator>
      <last_name>Barbara Grube, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 6, 2013</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
